Jeffrey T Kirby

Author PubWeight™ 10.37^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).	J Clin Microbiol	2009	1.52
2	Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.	Diagn Microbiol Infect Dis	2008	1.50
3	Initial results from a longitudinal international surveillance programme for anidulafungin (2003).	J Antimicrob Chemother	2004	1.33
4	Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).	J Clin Microbiol	2010	1.22
5	Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).	Diagn Microbiol Infect Dis	2007	1.20
6	Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).	Diagn Microbiol Infect Dis	2002	1.05
7	In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.	Diagn Microbiol Infect Dis	2004	0.95
8	CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance.	Ann Pharmacother	2003	0.91
9	Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.	Diagn Microbiol Infect Dis	2007	0.88